Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aortic endografts (EVAR/TEVAR) cases in Nevada: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (139 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 178 | 42% |
| 2020 | 0 | 135 | 45% |
| 2021 | 0 | 118 | 48% |
Endovascular abdominal and thoracic aortic repair. Professional codes (what the surgeon bills): CPT 34701, 34702, 34703, 34704, 34705, 34706, 33880, 33881; the hospital bills MS-DRG 268, 269, 213, 209.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 6 | 979−4.9%/yr | −4.9%/yr | 0.3 | 0% | 1,400 in 2030+6.1%/yr |
| Arizona | 3 | 322 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 20 | 2,124−8.8%/yr | −8.8%/yr | 7.71.6× | 96% | 2,190 in 2030+0.5%/yr |
| Superficial venous ablation |
Aortic endografts (EVAR/TEVAR) in every state, and its device makers · Every procedure market in Nevada · Every state · Compare with California
| 2024 |
| 117 |
| 56% |
| 2025 est. | ≈ 100 | – |
| 2026 est. | ≈ 100 | – |
| 2022 | 0 | 100 | 51% |
| 2023 | 0 | 112 | 54% |
| 2024 | 0 | 117 | 56% |
| 2025 from claims | – | 96 77–112 | 57% |
| 2026 forecast | – | 97 76–122 | 57% |
| 2027 forecast | – | 98 73–130 | 58% |
| 2028 forecast | – | 99 70–137 | 58% |
| 2029 forecast | – | 100 68–144 | 59% |
| 2030 forecast | – | 101 66–150 | 60% |
In 2025, 100% inpatient hospital.
| −6.9%/yr |
| 0.4 |
| 0% |
| 370 in 2030+2.5%/yr |
| Washington | 3 | 302−6.6%/yr | −6.6%/yr | 0.4 | 0% | 230 in 2030−4.4%/yr |
| Colorado | 0 | 174−6.8%/yr | −6.8%/yr | 0.4 | 0% | 200 in 2030+2.7%/yr |
| Oregon | 0 | 169−9.9%/yr | −9.9%/yr | 0.4 | 0% | 170 in 2030−0.3%/yr |
| 19 |
| 2,060−8.7%/yr |
| −8.7%/yr |
| 6.81.2× |
| 99% |
| 2,270 in 2030+1.7%/yr |
| Peripheral arterial intervention | 9 | 1,215−6.2%/yr | −6.2%/yr | 4.00.8× | 73% | 1,790 in 2030+6.7%/yr |
| Thrombectomy, IVC filters & venous stents | 3 | 412−4.7%/yr | −4.7%/yr | 1.41.2× | 0% | 540 in 2030+4.7%/yr |
| Carotid revascularization | 11 | 315−0.4%/yr | −0.4%/yr | 1.11.3× | 0% | 610 in 2030+11%/yr |
No metro breakdown yet.
W L Gore & Associates leads with 35% of company spending on these surgeons in 2025, +14 pts on 2024.
In 2025, 5 companies reported engagement with Nevada’s surgeons worth $51K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 36 clearances and approvals in the category, 2 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.